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A range of N-acylpyrrolo[3,4-c]isoxazoles and derived N-5 
acyltetramides has been prepared via a nitrile oxide dipolar 
cycloaddition approach, as analogues of the acyltetramic acid 
metabolite reutericyclin, of interest for their antibiotic 
potential against Gram-positive bacteria including hospital-
acquired infections of resistant Clostridium difficile. 10 
In order to combat the growing resistance to generally 
administered antibiotics, such as penicillin and methicillin, the 
research community is endeavouring to find new compounds that 
actively inhibit problematic resistant bacteria.1 This effort has 
identified a number of potential candidates, one example of 15 
which is reutericyclin (1), isolated in 2000 by Jung et al. from 
Lactobacillius reuteri LTH2584.2 Reutericyclin belongs to the 3-
acyltetramic acid group of natural products (2), characterised by a 
pyrrolidine-2,4-dione unit carrying an acyl group at C-3.3 
Molecules containing this motif exhibit a range of bio-activities 20 
including antibiotic, antitumor, antiviral, antiulcerative, 
fungicidal and cytotoxic properties.4 Interest in the antibiotic 
activity of tetramic acids has recently been stimulated by their 
key relationship to the inducers of bacterial quorum sensing.5 
Reutericyclin and derivatives display varying inhibition in Gram-25 
positive bacteria.2,6 The most interesting of these results is the 
inhibition of growth of resistant bacterium Clostridium difficile, a 
leading cause of antibiotic-associated diarrhoea in hospitalized 
patients which can lead to mortalities in persons with a 
compromised immune system.7 30 
 
 We have, over many years, explored the synthesis of the 
acyltetramic acid moiety8 and other cyclic tricarbonyl systems,9 
most recently using pyrroloisoxazoles as masked acyltetramic 
acids and as core building blocks for peripheral elaboration.10,11 35 
Our 2nd generation strategy (Scheme 1)10 uses pyrrolo[3,4-
c]isoxazoles 3 (cf. pyrrolo[3,4-d]isoxazoles in our 1st generation 
approach11) formed by cycloaddition of nitrile oxides 4, available 
in three steps from α-amino esters, with enamino ester 
dipolarophiles. We report here significant practical improvements 40 
in this strategy (principally in lactam closure) and its application 
to access novel bicyclic reutericyclin analogues. Reutericyclin 
has R-configuration at C-5, and is presumably biosynthesised 
from R-leucine,3,12 however we have conducted our studies in the 
more readily available S-series: the chemistry should, of course, 45 
be equally applicable to the enantiomeric series.13 
 
Scheme 1. The pyrrolo[3,4-c]isoxazole strategy (P = protecting group) 
 The commercially available methyl esters of S-valine, S-
leucine and S-phenylglycine were efficiently N-protected (Boc2O, 50 
Et3N, CH2Cl2, 0–20 ºC; 99, 97 and 99%, respectively). The 
protected amino esters (5a-c, respectively) were selectively 
reduced to the corresponding aldehydes using DIBAL-H at –78 
ºC (91, 93 and 87%), which were converted directly to the oximes 
6a-c (H2NOH.HCl, NaOAc, aq. EtOH, 2-8 ºC; 86, 79 and 88%) 55 
to inhibit potential epimerisation (Scheme 2). Treatment with 
NCS (CHCl3 reflux) afforded C-chloro-oximes 7, either used 
directly (7a,c) or isolated (7b; 75%); an extended reaction time 
for chlorination (18 h) led to better results when using the 
hydroximoyl chlorides 7 (vide infra) than in our previous reports. 60 
 
Scheme 2. Synthesis of pyrroloisoxazoles. 10. a, R1 = CHMe2; b, R1 = 
CH2CHMe2; c, R1 = Ph. Reagents: i, DIBAL-H, toluene, –78 ºC; ii, 
H2NOH.HCl, NaOAc, aq. EtOH, 2–8 ºC; iii, NCS, CHCl3 reflux, 18 h; iv, 
Et3N, CHCl3 reflux; v, TFA, 20ºC; 2M aq. HCl; vi, T3P, EtOAc, 0–20 ºC, 65 
17 h (with 9a,b) or PS-CDI, Et3N, DMF-CH2Cl2, 20 ºC, 17 h (with 9c) 
 The key dipolar cycloaddition step was performed by addition 
of Et3N to the chloro-oximes in the presence of the pyrrolidine 
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enamine of tert-butyl acetoacetate and pyrrolidine (separately 
prepared; toluene reflux, Dean-Stark conditions; 99%) to form 
the nitrile oxide in situ and complete the cycloaddition (CHCl3 
reflux) to afford isoxazoles 8a,c (49 and 56% from 6a,c) and 8b 
(60% from 7b). Simultaneous deprotection of the N-Boc amine 5 
and tert-butyl ester cleavage was achieved by acid treatment 
(TFA, 20 ºC; then 2M aq. HCl to give hydrochloride salts of 
better stability for handling and on storage) to leave amino acid 
salts 9a-c (99, 70 and 68%). 
 The final stage in assembly of the pyrroloisoxazoles, closure of 10 
the pyrrolo ring, was initially completed by our previously 
reported method using N-[3-(dimethylamino)propyl]-N'-
ethylcarbodiimide hydrochloride (EDCI) (N-hydroxysuccinimide, 
Et3N, DMF, 0-20 ºC) which required column chromatography 
and yielded the pyrroloisoxazoles 10a,b in unreliable yields 15 
(ranging 8–60%).10b Other peptide coupling reagents were 
investigated: whilst PyBroP failed, HATU did produce 10a in 
40% yield.14 The variable performance could be improved by 
using a polystyrene-supported carbodiimide (supplied as PS-CDI; 
Argonaut Technologies™) (Et3N, DMF-CH2Cl2, 20 ºC, 17 h) that 20 
reliably afforded 10a (66%), still however requiring column 
chromatographic purification and a costly alternative. Finally the 
simplest and most reliable lactam closure was achieved using the 
recently commercialised cyclic propylphosphonic anhydride 
(supplied as T3P; Archemica™).15 Thus a base (Et3N) was added 25 
to the salts 10a,b in EtOAc followed by T3P (0-20 ºC, 17 h). The 
pyrroloisoxazoles 10a,b were isolated pure without needing 
chromatography in good yields (59 and 68%). The 
phenylglycine-derived 10c was unsuccessful with T3P but could 
be prepared reliably by the PS-CDI protocol (50%). We have thus 30 
revealed two improved protocols for lactam closure to 
pyrroloisoxazoles 10: using T3P or PS-CDI. 
 The last stage in the synthesis of the masked reutericyclin 
analogues was to perform an N-acylation. As base we selected to 
use BuLi (THF, –78 ºC). Carboxylic esters were investigated as 35 
acylating agents but without success. However, acyl chlorides 
proved to be effective acylating agents to produce the N-acyl 
derivatives 11 (Scheme 3).13 A variety of acyl chlorides were 
selected including long and short aliphatic chains, an α,β-
unsaturated chain, a hindered branched moiety and an aromatic 40 
substituent, and all afforded N-acyl products 11 in yields of 33-
97% (Table 1).† Longer chain, aromatic or more hindered acyl 
chlorides required a slightly longer time for complete reaction 
than the shorter, unhindered, examples; a standard reaction time 
of 3 h was eventually employed. The constitution of the N-(but-2-45 
enyl)-6-(2-methylpropyl)pyrroloisoxazole 11c was confirmed by 
an X-ray crystal structure (Fig. 1).‡ 
 
Figure 1. X-Ray crystal structure of N-acyl pyrroloisoxazole 11c. O = 
red, N = Blue, C = grey, H = light gey. 50 
 
Scheme 3. N-Acylation of pyrroloisoxazoles 10, see Table 1 
Table 1. Masked reutericyclin analogues: N-acyl pyrroloisoxazoles 11 
   
   
   
   
 
 This completed the synthesis of the reutericyclin analogues. 55 
Next we determined to create some tetramide analogues, by N–O 
bond cleavage of the pyrroloisoxazole nucleus. This was 
achieved for bicycles 11a,f by hydrogenolysis (1 atm H2, Pd-C) 
to afford the enaminoketones (tetramides) 12a,b (49 and 52%) 
(Scheme 4). To demonstrate an alternative protocol, and because 60 
hydrogenation would be likely to reduce an unsaturated N-acyl 
group,10b N–O cleavage of 11l was accomplished by Mo(CO)6 
(aq. MeCN; then 2M aq. HCl) to give enaminoketone 12c 
(60%).16 Attempted hydrolysis of the enamine to generate 
acyltetramic acid either returned unchanged enaminoketone (e.g. 65 
H2O at 20 ºC or 2M aq. HCl at reflux; NaNO2, 3M aq. H2SO4) or 
led to N-deacylation (aq. NaOH, 2M at reflux or 0.1M at 20 ºC). 
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Scheme 4. Formation of N-acyltetramides 12 from pyrroloisoxazoles 11 
 In conclusion, we have developed a synthetic route, based on a 
nitrone 1,3-dipolar cycloaddition, from amino acids to N-
acylpyrrolo[3,4-c]isoxazoles 11 as reutericyclin analogues, and 5 
presented a diverse selection of 12 novel compounds. 
Furthermore, we have demonstrated the conversion of these 
heterobicycles into N-acyltetramides 12. All of these new 
compounds are currently undergoing biological evaluation. 
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† Typical procedure for N-acylpyrrolo[3,4-c]isoxazole formation: (S)-5-
Butyryl-6-isopropyl-3-methyl-5,6-dihydro-4H-pyrrolo[3,4-c]isoxazol-4-
one 11a. (S)-6-(1-Methylethyl)-3-methyl-5,6-dihydro-4H-pyrrolo[3,4-
c]isoxazol-4-one 10a (50.0 mg, 0.277 mmol) was suspended in dry THF 20 
(20 mL) stirred at –78 ºC under a nitrogen atmosphere. n-Butyl-lithium 
(0.201 mL, 1.41M in hexanes, 0.283 mmol) was added and the reaction 
stirred for 15 min at this temperature, during which time the solution 
turned yellow. Butanoyl chloride (29.6 mg, 27.0 µL, 0.283 mmol) was 
then added in two portions over 10 min and the mixture stirred at –78 ºC 25 
for a further 3 h before quenching by addition of satd. NH4Cl solution. 
The mixture was tested for pH to ensure neutrality had been achieved and 
then separated between water (20 mL) and EtOAc (25 mL). The organic 
layer was dried over MgSO4, filtered and concentrated under reduced 
pressure to produce the title compound 11a as a yellow oil (62 mg, 89%); 30 
[α]D20 +36.0 (c 5.00 x 10–3, CHCl3); νmax(CHCl3)/cm–1 3025, 1725 (C=O), 
1689 (C=O), 1650, 1389, 1250, 1131; δH (400MHz; CDCl3) 0.50 (3H, d, J 
= 6.8, CH(CH3)2) 0.92 (3H, t, J = 7.2, CH2CH3), 1.17 (3H, d, J = 6.8, 
CH(CH3)2), 1.55-1.61 (2H, m, CH2CH3), 2.61 (3H, s, 3-CH3), 2.68-2.72 
(1H, m, CH(CH3)2), 2.81, 2.92 (each 1H, dt, J = 7.6, 14.8, CH2CO), 5.13 35 
(1H, d, J = 4, CHN); δC (100MHz; CDCl3) 11.8, 12.8, 13.1 (CH3), 17.0 
(CH2CH3), 17.9 (CH3), 27.0 (CH(CH3)2), 38.2 (CH2CO), 59.9 (CHN), 
113.0, 159.5, 165.0 (Isoxazole-C), 168.6, 173.2 (CO). HRMS (ESI): 
MNa+ 273.1211; C13H18N2O3 requires MNa+ 273.1210. 
‡ Crystal data for 11c: C13H16N2O3, M = 248.28, orthorhombic, P212121, a 40 
= 6.9698 (12), b = 9.5108 (16), c = 19.233 (3) Å, V = 1274.9 (4) Å3, Z = 
4, μ(Mo-Kα) = 0.71073 Å, 11350 reflections measured at 150 K on a 
Bruker APEX 2 CCD diffractometer, 2618 unique data, Rint = 0.034, R[for 
2390 data with F2 > 2σ(F2)] = 0.032, wR2 (all data) = 0.078, 227 
parameters. H atoms were freely refined. Absolute structure {x = 0.0(6)} 45 
could not be determined reliably. CCDC 959645. 
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